My initial comment about the reduction was not about the media. My initial comment was about the fact that we, in 2004, started to really sit down and educate all of our patients around the risks, benefits, and potential adverse effects of all of the choices for antimalarials, which, I believe, made a difference.
Mefloquine has been controversial since the nineties. We saw that fall out of the Somalia inquiries and the discussion around mefloquine at that time. I think that my statement with respect to media impact is not just from, I believe you said, 2013, since when there has been some discussion about it. Throughout the nineties and 2000s there has been controversy around mefloquine, which, I believe, shaped some people's decisions, in addition to, as I said, the education and discussions that we started to have seriously with patients in 2004.